Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Evogliptin/Metformin XR FDC vs Co-administration and Food Effect
NCT02167061Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Jul 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DA5221-B2 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Dong-A ST. Primary endpoints: Area Under Curve(AUC)last of Evogliptin and Metformin at 72 hours and Maximum of concentration (Cmax) of Evogliptin and Metformin at 72 hours. Started Jul 2014; status: completed.
02
Drugs
DA5221-B2
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02167061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02167061.